A Major National Program Is Needed To Solve The Mysteries Of Aging

This century's march of increasing life expectancy has almost reached an end, at least in the developed countries. Better nutrition, medical care, public health facilities, and accident prevention have helped boost life expectancy at birth from 47.9 years in 1900 to 69.2 years in the mid-1950s and then, more slowly, to 74.9 years in 1989. But conventional billion-dollar disease research to further decrease premature deaths is becoming progressively more futile, thanks to limits imposed not by d

Written byDenham Harman
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This century's march of increasing life expectancy has almost reached an end, at least in the developed countries. Better nutrition, medical care, public health facilities, and accident prevention have helped boost life expectancy at birth from 47.9 years in 1900 to 69.2 years in the mid-1950s and then, more slowly, to 74.9 years in 1989.

But conventional billion-dollar disease research to further decrease premature deaths is becoming progressively more futile, thanks to limits imposed not by disease, but by the mysterious, inexorable, universal, and subtle phenomenon we call aging. The accelerating nature of the aging process has been revealed by improvements in our living conditions, which have decreased young people's chances of death more than they have decreased their elders'. In fact, the chance of death now increases almost exponentially after about age 28, in accordance with the aging process. The effects of environment and disease become greater with advancing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies